Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00383045 · ClinicalTrials.gov registry record · Phase 2
HIV Risk Reduction and Drug Abuse Treatment in Malaysia
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00383045 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 180 participants.
The verdict
NCT00383045, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
A randomized clinical trial comparing drug abuse and HIV risk reduction counseling (DC-HIV) alone, DC-HIV combined with naltrexone maintenance, and DC-HIV combined with buprenorphine maintenance for the treatment of heroin addicts in Malaysia.
Interventions
- DRUG Naltrexone
- DRUG Buprenorphine/Subutex
- PROCEDURE Drug counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2003-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00383045
The ClinicalTrials.gov registry entry for NCT00383045 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Naltrexone is the first listed.
NCT00383045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00383045 about?
NCT00383045 is a clinical study titled "HIV Risk Reduction and Drug Abuse Treatment in Malaysia". A randomized clinical trial comparing drug abuse and HIV risk reduction counseling (DC-HIV) alone, DC-HIV combined with naltrexone maintenance, and DC-HIV combined with buprenorphine maintenance for the treatment of heroin addicts in Malaysia.
What is the current status of trial NCT00383045?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2003-04. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00383045?
The interventions under investigation include: Naltrexone (DRUG), Buprenorphine/Subutex (DRUG), Drug counseling (PROCEDURE).
Who is sponsoring clinical trial NCT00383045?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.